Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Lymphoma 7Lymphoma, Follicular 6Lymphoma, Non-Hodgkin 5Lymphoma, Large B-Cell, Diffuse 4Lymphoma, B-Cell, Marginal Zone 4Lymphoma, Mantle-Cell 3Recurrence 2Advanced Malignancies 2Unresectable or Metastatic Solid Tumors 1Pancreatic Neoplasms 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, B-Cell 1Lung Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Breast Neoplasms 1B-Cell Malignancies 1

Interventions

parsaclisib 1epacadostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Unresectable or Metastatic Solid Tumors × parsaclisib × Clear all
NCT03589651 2023-02-21

INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors

Incyte Corporation

Phase 1 Completed
83 enrolled
Other solid neoplasm

Unresectable or Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡